SELLAS Life Sciences develops licensed cancer drugs, led by the galinpepimut-S (GPS) vaccine for acute myeloid leukaemia and the kinase inhibitor tambiciclib (SLS009).
Latest research: initiation, Nov 19, 2026 · Market value $3,897.6m
SLSSellTarget $8.77−54% expected
Our view, Nov 19, 2026
SELLAS’s vaccine works, but its market is too small for a $3.9bn price
SELLAS is a 13-employee biotech whose leukaemia vaccine GPS just extended survival in a Phase 3 trial, and the shares jumped 156%. The market now prices more patients than the disease provides, and we see 54% downside.
What the shares could be worth
Circle size shows how likely we think each case is. Case values are present values; the target weights all three and rolls forward 12 months at an 11.1% cost of equity. Source: Penmark Research.
FDA requires a confirmatory trial, cutting CR2 approval odds to 40% and delaying launch to FY29E: −$0.67 a share (indicative).
Menin inhibitors and venetoclax combinations shrink GPS's CR2 share to 30%: −$0.58 a share (indicative).
Payers cap US GPS net price at $200k a year: −$0.58 a share (indicative).
What bulls get right. No approved therapy holds randomised survival proof in unfit second remission, and short interest of 28.1% can keep the shares detached from value.
Dates to watch
We assume $17.00 a share for the $150m offering.
SLS009 data and doctors’ and payers’ views on GPS pricing; we model $300k a year.
Results for patients who had venetoclax, and whether the FDA asks for a confirmatory trial.
We model $19.0m of risk-adjusted FY28E sales; analysts expect $122m.
Is SELLAS Life Sciences Group stock a buy, hold or sell?
Penmark Research rates SELLAS Life Sciences Group (SLS) Sell, with a 12-month price target of $8.77, -54% from the $19.15 share price at our latest report. We expect a total return worse than −10% over the next 12 months: a fall of more than 10%, after dividends.
What is the SLS price target?
Our 12-month price target for SELLAS Life Sciences Group is $8.77, set in our initiation of Nov 19, 2026. Our bear case values the shares at $0.18 and our bull case at $26.77. The target comes from the probability-weighted value of our bull, base and bear cases.
Will SELLAS Life Sciences Group stock go up?
Our SELLAS Life Sciences Group stock forecast is a 12-month price target of $8.77, -54% from the $19.15 share price at our latest report, which is why we rate it Sell. Our bear case puts the shares at $0.18 (-99%) and our bull case at $26.77 (+40%). No forecast is certain; the main risks are below.
What does SELLAS Life Sciences Group do?
SELLAS Life Sciences develops licensed cancer drugs, led by the galinpepimut-S (GPS) vaccine for acute myeloid leukaemia and the kinase inhibitor tambiciclib (SLS009).
What are the main risks to SELLAS Life Sciences Group stock?
FDA requires a confirmatory trial, cutting CR2 approval odds to 40% and delaying launch to FY29E: −$0.67 a share (indicative).
Menin inhibitors and venetoclax combinations shrink GPS's CR2 share to 30%: −$0.58 a share (indicative).
Payers cap US GPS net price at $200k a year: −$0.58 a share (indicative).
What is Penmark’s latest research on SELLAS Life Sciences Group?
Our latest report is our initiation of Nov 19, 2026, “Positive Phase 3 survival data cannot justify a $3.9bn valuation; initiate at Sell”. We initiate on SELLAS Life Sciences at Sell with an $8.77 target, 54.2% below the $19.15 close. Phase 3 REGAL met overall survival in second remission, but only about 1,700 unfit US adults enter CR2 a year, and even 100% approval odds value SLS at $6.36 a share. The price implies $4.9bn of peak US GPS sales, 3.4x our…